At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
The move signals a major expansion in access to next-generation weight-loss therapies
The filing is backed by Phase III data from the lidERA Breast Cancer study
Subscribe To Our Newsletter & Stay Updated
